Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
添加氟和口服 SERD AZD9833 的后期功能化 (LSF),ACS Medicinal Chemistry Letters - X-MOL
A trial of AZD9833 for breast cancer (SERENA-4) | Cancer Research UK
Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 ...
阿斯利康乳腺癌新药 AZD9833 国内获批临床 2 月 20 日，CDE 官网显示， 阿斯利康 的雌激素受体拮抗剂 AZD9833 首次在 ...
Estudio de AZD9833 y un inhibidor de CDK4/6 en pacientes con cáncer de ...
Discovery of AZD9833, a potent and orally bioavailable selective ...
Camizestrant (AZD9833) | Estrogen Receptor Antagonist | CAS 2222844-89 ...
新药研发：阿斯利康临床I期ER降解剂&拮抗剂AZD9833的发现|阿斯利康|降解剂|拮抗剂|化合物|乳腺癌|细胞株|-健康界
The Next-Generation Oral Selective Estrogen Receptor Degrader ...
Illustration of the drug camizestrant (AZD9833). Camizestrant is an ...
AZD-9833 | CAS#:2222844-89-3 | Chemsrc
AZD-9833 is an Orally Active Estrogen Receptor (ER) Antagonist ...
Chemspace | Analogs to New Biological Tool Compounds | Camizestrant ...
阿斯利康口服SERD乳腺癌II期研究成功 10月26日， 阿斯利康 宣布，其下一代口服选择性雌激素受体降解剂（SERD ...
Camizestrant, AZD 9833 « New Drug Approvals
Addition of Fluorine and a Late-Stage Functionalization (LSF) of the ...
camizestrant (AZD9833) / AstraZeneca
ISSX 2022 - Hypha Discovery
Abstract 5674: Discovery of AZD9833, an oral small molecule selective ...
Abstract P3-07-13: The next generation oral selective estrogen receptor ...
Abstract PO3-19-09: SERENA-1: Results from a Phase 1 study (Parts I/J ...
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of ...
Discovery of novel covalent selective estrogen receptor degraders ...
Frontiers | Next generation selective estrogen receptor degraders in ...
Camizestrant (AZD-9833) | Estrogen Receptor Antagonist | MedChemExpress
Identification, synthesis and characterization of a unique N ...
Camizestrant TFA | Estrogen Receptor/ERR | TargetMol
AstraZeneca Leading Revolution in Precision Oncology Therapy: The ...
CAMBRIA-2: An Adjuvant Endocrine-based Therapy Study of Camizestrant ...
医药魔方
Study on the Effects and Safety of Camizestrant (AZD9833) Compared to ...
AZD-9833 (Camizestrant); Estrogen receptor antagonist 2 - 小分子，大梦想
Frontiers | Optimization of small molecule degraders and antagonists ...
Targeting Breast Cancer: An Overlook on Current Strategies
A phase I study of RAD1901, an oral selective estrogen receptor ...
Ten Ways Degraders Differentiate from Traditional Small Molecules
Selective Estrogen Receptor Degrader/Modulator RAD1901 | Semantic Scholar
Camizestrant (AZD-9833) | CAS#2222844-89-3 MCE貨號HY-136255
Abstract OT-09-02: A randomized, open-label, parallel-group ...
tilatamig samrotecan (AZD9592) / AstraZeneca
AstraZeneca demonstrated the significant findings from the SERENA...
Global Targeted Protein Degraders 2025 - Preview Copy.pdf
Buy Other Targets | Life Sciences - Ligands Products | Biosynth
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC ...
SERDs in HR+HER2- Breast Cancer | PDF
阿斯利康第二代PARP1抑制剂AZD5305联合AZD9833治疗BRCA或PALB2突变的晚期乳腺癌患者 - 知乎
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal ...
Structure d’un ARNt et complémentarité codon-anticodon | Planet-Vie
氟维司群回归医保，CSCO乳腺癌指南I级推荐！
ER inhibition by ER antagonist, PROTAC, and MGDs. Target proteins ...
Mechanism of action of Orserdu as SERM and SERD | Download Scientific ...
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast ...
